Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Majumder, Mousumi ^a   Tutunea Fatan, Elena ^a   Xin, Xiping ^a   Rodriguez Torres, Mauricio ^a   Torres Garcia, Jose ^a   Wiebe, Ryan ^a   Ti moshenko, Alexander V ^a   Bhattacharjee, Rabindra N ^a   Chambers, Ann F ^a   Lala, Peeyush K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA9BETA1 INTEGRIN; CYCLOOXYGENASE 2; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; INTEGRIN ALPHA 9 BETA 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER CELL CULTURE; CAPILLARY TUBE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; ANIMAL; BREAST; BREAST TUMOR; CANCER INVASION; CELL MOTION; CYTOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRINS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84860163103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035094     Document Type: Article

References (58)

1. Truong PT, Vinh-Hung V, Cserni G, Woodward WA, Tai P, et al. (2008) The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer 44: 1670-1677.
2. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K, (2004) Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25: 387-395.
3. Wissmann C, Detmar M, (2006) Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 12: 6865-6868.
4. Yang W, Klos K, Yang Y, Smith TL, Shi D, et al. (2002) ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 94: 2855-2861.
5. Van dA, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, et al. (2004) Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 10: 7965-7971.
6. Mohammed RA, Green A, El Shikh S, Paish EC, Ellis IO, et al. (2007) Prognostic significance of vascular endothelial cell growth factors-A,-C and-D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96: 1092-1100.
7. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK, (2006) COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 94: 1154-1163.
8. Bhattacharjee RN, Timoshenko AV, Cai J, Lala PK, (2010) Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Sci 101: 2026-2032.
9. Timoshenko AV, Rastogi S, Lala PK, (2007) Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 97: 1090-1098.
10. Vantyghem SA, Allan AL, Postenka CO, Al Katib W, Keeney M, et al. (2005) A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis 22: 351-361.
11. Vlahakis NE, Young BA, Atakilit A, Sheppard D, (2005) The lymphangiogenic vascular endothelial growth factors VEGF-C and-D are ligands for the integrin alpha9beta1. J Biol Chem 280: 4544-4552.
12. Martinetti A, Bajetta E, Ferrari L, Zilembo N, Seregni E, et al. (2004) Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 11: 771-779.
13. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, et al. (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11: 4646-4652.
14. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, et al. (2006) Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169: 233-246.
15. Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, et al. (2008) Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res 10: R62.
16. Xu J, Chambers AF, Tuck AB, Rodenhiser DI, (2008) Molecular cytogenetic characterization of human breast cancer cell line MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis. Cancer Genet Cytogenet 181: 1-7.
17. Pandit TS, Kennette W, Mackenzie L, Zhang G, Al Katib W, et al. (2009) Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35: 297-308.
18. Iivanainen E, Nelimarkka L, Elenius V, Heikkinen SM, Junttila TT, et al. (2003) Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J 17: 1609-1621.
19. Gimi B, Mori N, Ackerstaff E, Frost EE, Bulte JW, et al. (2006) Noninvasive MRI of endothelial cell response to human breast cancer cells. Neoplasia 8: 207-213.
20. Decaestecker C, Debeir O, Van Ham P, Kiss R, (2007) Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 27: 149-176.
21. Zeng Y, Opeskin K, Baldwin ME, Horvath LG, Achen MG, et al. (2004) Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 10: 5137-5144.
22. Ji RC, (2006) Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat Res Biol 4: 83-100.
23. Shields JD, Emmett MS, Dunn DB, Joory KD, Sage LM, et al. (2007) Chemokine-mediated migration of melanoma cells towards lymphatics-a mechanism contributing to metastasis. Oncogene 26: 2997-3005.
24. Mikhaylova M, Mori N, Wildes FB, Walczak P, Gimi B, et al. (2008) Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia 10: 380-389.
25. McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N, et al. (2007) Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J 21: 1088-1098.
26. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, et al. (2000) VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 14: 2087-2096.
27. Lewis CE, Pollard JW, (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612.
28. Watari K, Nakao S, Fotovati A, Basaki Y, Hosoi F, et al. (2008) Role of macrophages in inflammatory lymphangiogenesis: Enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation. Biochem Biophys Res Commun 377: 826-831.
29. Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, et al. (2004) VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J 18: 1111-1113.
30. Pan MR, Chang TM, Chang HC, Su JL, Wang HW, et al. (2009) Sumoylation of Prox1 controls its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells. J Cell Sci 122: 3358-3364.
31. Lin CH, Lu J, Lee H, (2011) Interleukin-1beta expression is required for lysophosphatidic Acid-induced lymphangiogenesis in human umbilical vein endothelial cells. Int J Inflam 2011 351010.
32. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, et al. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752.
33. Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, et al. (2006) A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res 8: R69.
34. Bertl E, Bartsch H, Gerhauser C, (2006) Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther 5: 575-585.
35. Liu T, Jabbes M, Nedrow-Byers JR, Wu LY, Bryan JN, et al. (2011) Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. Int J Oncol 38: 1349-1355.
36. Sleeman JP, Thiele W, (2009) Tumor metastasis and the lymphatic vasculature. Int J Cancer 125: 2747-2756.
37. Rousseau S, Houle L, Landry J, Huot J, (1997) p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15: 2169-2177.
38. Henriksen K, Karsdal M, Delaisse JM, Engsig MT, (2003) RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 278: 48745-48753.
39. Jadeski LC, Lala PK, (1999) Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 155: 1381-1390.
40. Belien JA, Somi S, de Jong JS, van Diest PJ, Baak JP, (1999) Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. J Clin Pathol 52: 184-192.
41. Khodarev NN, Yu J, Labay E, Darga T, Brown CK, et al. (2003) Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 116: 1013-1022.
42. Marchio S, Primo L, Pagano M, Palestro G, Albini A, et al. (1999) Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem 274: 27617-27622.
43. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K, (2004) Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 46: 11-19.
44. Shang T, Yednock T, Issekutz AC, (1999) alpha9beta1 integrin is expressed on human neutrophils and contributes to neutrophil migration through human lung and synovial fibroblast barriers. J Leukoc Biol 66: 809-816.
45. Nishimichi N, Higashikawa F, Kinoh HH, Tateishi Y, Matsuda H, et al. (2009) Polymeric osteopontin employs integrin alpha9beta1 as a receptor and attracts neutrophils by presenting a de novo binding site. J Biol Chem 284: 14769-14776.
46. Hedley BD, Welch DR, Allan AL, Al Katib W, Dales DW, et al. (2008) Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 123: 526-534.
47. Rudland PS, Platt-Higgins A, El Tanani M, De Silva RS, Barraclough R, et al. (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427.
48. Tuck AB, Chambers AF, Allan AL, (2007) Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102: 859-868.
49. Huang XZ, Wu JF, Ferrando R, Lee JH, Wang YL, et al. (2000) Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol Cell Biol 20: 5208-5215.
50. Allen MD, Vaziri R, Green M, Chelala C, Brentnall AR, et al. (2011) Clinical and functional significance of α9β1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol 223: 646-658.
51. Oommen S, Gupta SK, Vlahakis NE, (2011) Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site. J Biol Chem 286: 1083-1092.
52. Vlahakis NE, Young BA, Atakilit A, Hawkridge AE, Issaka RB, et al. (2007) Integrin alpha9beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis. J Biol Chem 282: 15187-15196.
53. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, et al. (1987) Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci U S A 84: 4621-4625.
54. van I, V, Leidenius M, von Smitten K, Bono P, Heikkila P, (2007) VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am J Clin Pathol 128: 759-766.
55. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, et al. (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186-191.
56. Gu Y, Qi X, Guo S, (2008) Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases. Clin Exp Metastasis 25: 717-725.
57. Rozic JG, Chakraborty C, Lala PK, (2001) Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506.
58. Sonvilla G, Allerstorfer S, Stättner S, Karner J, Klimpfinger M, et al. (2008) FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis 29: 15-24.